Journal of Personalized Medicine,
Год журнала:
2024,
Номер
14(11), С. 1092 - 1092
Опубликована: Ноя. 4, 2024
After
the
COVID-19
pandemic,
mRNA-based
vaccines
have
emerged
as
a
revolutionary
technology
in
immunization
and
vaccination.
These
shown
remarkable
efficacy
against
virus
opened
up
avenues
for
their
possible
application
other
diseases.
This
has
renewed
interest
investment
mRNA
vaccine
research
development,
attracting
scientific
community
to
explore
all
its
applications
beyond
infectious
Recently,
researchers
focused
on
possibility
of
adapting
this
vaccination
approach
cancer
immunotherapy.
While
there
is
huge
potential,
challenges
still
remain
design
optimization
synthetic
molecules
lipid
nanoparticle
delivery
system
required
ensure
adequate
elicitation
immune
response
successful
eradication
tumors.
review
points
out
basic
mechanisms
mRNA-LNP
immunotherapy
recent
approaches
design.
displays
current
modifications
components
how
these
factors
affect
efficacy.
Furthermore,
discusses
future
directions
clinical
treatment.
Abstract
Cancer
nanovaccines
represent
a
promising
frontier
in
cancer
immunotherapy,
utilizing
nanotechnology
to
augment
traditional
vaccine
efficacy.
This
review
comprehensively
examines
the
current
state‐of‐the‐art
nanovaccine
development,
elucidating
innovative
strategies
and
technologies
employed
their
design.
It
explores
both
preclinical
clinical
advancements,
emphasizing
key
studies
demonstrating
potential
elicit
robust
anti‐tumor
immune
responses.
The
study
encompasses
various
facets,
including
integrating
biomaterial‐based
nanocarriers
for
antigen
delivery,
adjuvant
selection,
impact
of
nanoscale
properties
on
performance.
Detailed
insights
into
complex
interplay
between
tumor
microenvironment
responses
are
provided,
highlighting
challenges
opportunities
optimizing
therapeutic
outcomes.
Additionally,
presents
thorough
analysis
ongoing
trials,
presenting
snapshot
landscape.
By
curating
latest
scientific
findings
developments,
this
aims
serve
as
comprehensive
resource
researchers
clinicians
engaged
advancing
immunotherapy.
Integrating
design
holds
immense
promise
revolutionizing
treatment
paradigms,
provides
timely
update
evolving
landscape
nanovaccines.
Journal of Microbiological Methods,
Год журнала:
2024,
Номер
224, С. 106998 - 106998
Опубликована: Июль 15, 2024
Vaccine
development
stands
as
a
cornerstone
of
public
health
efforts,
pivotal
in
curbing
infectious
diseases
and
reducing
global
morbidity
mortality.
However,
traditional
vaccine
methods
are
often
time-consuming,
costly,
inefficient.
The
advent
artificial
intelligence
(AI)
has
ushered
new
era
design,
offering
unprecedented
opportunities
to
expedite
the
process.
This
narrative
review
explores
role
AI
development,
focusing
on
antigen
selection,
epitope
prediction,
adjuvant
identification,
optimization
strategies.
algorithms,
including
machine
learning
deep
learning,
leverage
genomic
data,
protein
structures,
immune
system
interactions
predict
antigenic
epitopes,
assess
immunogenicity,
prioritize
antigens
for
experimentation.
Furthermore,
AI-driven
approaches
facilitate
rational
design
immunogens
identification
novel
candidates
with
optimal
safety
efficacy
profiles.
Challenges
such
data
heterogeneity,
model
interpretability,
regulatory
considerations
must
be
addressed
realize
full
potential
development.
Integrating
emerging
technologies,
single-cell
omics
synthetic
biology,
promises
enhance
precision
scalability.
underscores
transformative
impact
highlights
need
interdisciplinary
collaborations
harmonization
accelerate
delivery
safe
effective
vaccines
against
diseases.
Biomarker Research,
Год журнала:
2023,
Номер
11(1)
Опубликована: Дек. 1, 2023
Adoptive
cell
therapy
using
T
receptor-engineered
cells
(TCR-T)
is
a
promising
approach
for
cancer
with
an
expectation
of
no
significant
side
effects.
In
the
human
body,
mature
are
armed
incredible
diversity
receptors
(TCRs)
that
theoretically
react
to
variety
random
mutations
generated
by
tumor
cells.
The
outcomes,
however,
current
clinical
trials
TCR-T
therapies
not
very
successful
especially
involving
solid
tumors.
still
faces
numerous
challenges
in
efficient
screening
tumor-specific
antigens
and
their
cognate
TCRs.
this
review,
we
first
introduce
TCR
structure-based
antigen
recognition
signaling,
then
describe
recent
advances
neoantigens
specific
technologies,
finally
summarize
ongoing
against
neoantigens.
More
importantly,
also
present
cell-based
immunotherapies,
e.g.,
safety
viral
vectors,
mismatch
receptor,
impediment
suppressive
microenvironment.
Finally,
highlight
new
insights
directions
personalized
therapy.
Bioinformation,
Год журнала:
2024,
Номер
20(1), С. 29 - 35
Опубликована: Янв. 31, 2024
Rapid
advancements
in
the
field
of
artificial
intelligence
(AI)
have
opened
up
unprecedented
opportunities
to
revolutionize
various
scientific
domains,
including
immunology
and
genetics.
Therefore,
it
is
interest
explore
emerging
applications
AI
genetics,
with
objective
enhancing
our
understanding
dynamic
intricacies
immune
system,
disease
etiology,
genetic
variations.
Hence,
use
methodologies
immunological
datasets,
thereby
facilitating
development
innovative
approaches
realms
diagnosis,
treatment,
personalized
medicine
reviewed.
American Society of Clinical Oncology Educational Book,
Год журнала:
2024,
Номер
44(3)
Опубликована: Апрель 26, 2024
The
origins
of
cancer
vaccines
date
back
to
the
1800s.
Since
then,
there
have
been
significant
efforts
generate
against
solid
and
hematologic
malignancies
using
a
variety
platforms.
To
date,
these
generally
met
with
minimal
success.
However,
in
era
improved
methods
technological
advancements,
supported
by
compelling
preclinical
clinical
data,
wave
renewed
interest
field
offers
promise
discovering
field-changing
paradigms
management
established
resected
disease
vaccines.
These
include
novel
approaches
personalized
neoantigen
vaccine
development,
as
well
innovative
immune-modulatory
(IMVs)
that
facilitate
activation
antiregulatory
T
cells
limit
immunosuppression
caused
regulatory
immune
cells.
This
article
will
introduce
some
limitations
affected
development
over
past
several
decades,
followed
an
introduction
latest
advancements
IMV
therapy,
then
conclude
discussion
newest
technologies
progress
are
occurring
across
space.
Cancer
among
most
promising
frontiers
for
breakthrough
innovations
strategies
poised
make
measurable
impact
ongoing
fight
cancer.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Ноя. 8, 2024
Immunotherapy
has
ushered
in
a
new
era
of
cancer
treatment,
yet
remains
leading
cause
global
mortality.
Among
various
therapeutic
strategies,
vaccines
have
shown
promise
by
activating
the
immune
system
to
specifically
target
cells.
While
current
are
primarily
prophylactic,
advancements
targeting
tumor-associated
antigens
(TAAs)
and
neoantigens
paved
way
for
vaccines.
The
integration
artificial
intelligence
(AI)
into
vaccine
development
is
revolutionizing
field
enhancing
aspect
design
delivery.
This
review
explores
how
AI
facilitates
precise
epitope
design,
optimizes
mRNA
DNA
instructions,
enables
personalized
strategies
predicting
patient
responses.
By
utilizing
technologies,
researchers
can
navigate
complex
biological
datasets
uncover
novel
targets,
thereby
improving
precision
efficacy
Despite
AI-powered
vaccines,
significant
challenges
remain,
such
as
tumor
heterogeneity
genetic
variability,
which
limit
effectiveness
neoantigen
prediction.
Moreover,
ethical
regulatory
concerns
surrounding
data
privacy
algorithmic
bias
must
be
addressed
ensure
responsible
deployment.
future
lies
seamless
create
immunotherapies
that
offer
targeted
effective
treatments.
underscores
importance
interdisciplinary
collaboration
innovation
overcoming
these
advancing
development.
Gene
and
RNA-based
therapeutics
represent
a
promising
frontier
in
oncology,
enabling
targeted
modulation
of
tumor-associated
genes
proteins.
This
review
explores
the
latest
advances
payload
vectorization
delivery
systems
developed
for
vivo
cancer
treatments.
We
discuss
viral
non-viral
organic
particles,
including
lipid
based
nanoparticles
polymeric
structures,
effective
transport
plasmids,
siRNA,
self-amplifying
RNA
therapeutics.
Their
physicochemical
properties,
strategies
to
overcome
intracellular
barriers,
innovations
cell-based
carriers
engineered
extracellular
vesicles
are
highlighted.
Moreover,
we
consider
oncolytic
viruses,
novel
capsid
modifications,
approaches
that
refine
tumor
targeting
immunomodulation.
Ongoing
clinical
trials
regulatory
frameworks
guide
future
directions
emphasize
need
safe,
scalable
production.
The
potential
convergence
these
with
combination
therapies
paves
way
toward
personalized
medicine.
Current Research in Biotechnology,
Год журнала:
2024,
Номер
7, С. 100177 - 100177
Опубликована: Янв. 1, 2024
Since
millions
of
cancer-related
deaths
and
diagnoses
exist
yearly,
malignant
tumors
are
a
primary
worldwide
health
concern.
A
promising
method
for
treating
cancer
is
tumor
immunotherapy,
which
focuses
on
neoantigens.
Neoantigens
tumor-specific
antigens
expressed
cells
due
to
genetic
changes,
viral
infections,
or
other
biological
processes.
They
serve
as
excellent
immune
system
targets
identify
attack
cancerous
cells.
more
immunogenic
than
tumor-associated
(TAAs)
because
they
lack
central
tolerance.
Successful
clinical
trials
neoantigen-based
vaccines
have
raised
interest
in
individualized
immunotherapy.
Furthermore,
neoantigens
represent
significant
advancement
offering
the
potential
personalized
effective
treatments.
The
identification,
synthesis,
application
hold
promise
improving
patient
outcomes
revolutionizing
treatment
approaches.
This
review
significance
their
classification
synthesis
neoantigen
vaccines,
principles
underlying
therapeutic
efficacy.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Май 29, 2024
Cancer
immunotherapy
has
witnessed
rapid
advancement
in
recent
years,
with
a
particular
focus
on
neoantigens
as
promising
targets
for
personalized
treatments.
The
convergence
of
immunogenomics,
bioinformatics,
and
artificial
intelligence
(AI)
propelled
the
development
innovative
neoantigen
discovery
tools
pipelines.
These
have
revolutionized
our
ability
to
identify
tumor-specific
antigens,
providing
foundation
precision
cancer
immunotherapy.
AI-driven
algorithms
can
process
extensive
amounts
data,
patterns,
make
predictions
that
were
once
challenging
achieve.
However,
integration
AI
comes
its
own
set
challenges,
leaving
space
further
research.
With
computational
approaches,
this
article
we
explored
current
landscape
prediction,
fundamental
concepts
behind,
challenges
their
potential
solutions
comprehensive
overview
rapidly
evolving
field.
